1 / 5

Israel Conference, Tel Aviv, 24-3-05

Israel Conference, Tel Aviv, 24-3-05 MDMA/PTSD research in Spain. Preliminary data and future perspectives José Carlos Bouso Saiz ( jcbouso@gmail.com ) Cátedra de la “Fundación Cultural Fórum Filatélico de Psicobiología y Discapacidad” Departamento de Psicología Biológica y de la Salud

lamya
Download Presentation

Israel Conference, Tel Aviv, 24-3-05

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Israel Conference, Tel Aviv, 24-3-05 MDMA/PTSD research in Spain. Preliminary data and future perspectives José Carlos Bouso Saiz (jcbouso@gmail.com) Cátedra de la “Fundación Cultural Fórum Filatélico de Psicobiología y Discapacidad” Departamento de Psicología Biológica y de la Salud Facultad de Psicología Universidad Autónoma de Madrid 28049 Madrid Spain

  2. DOSE-FINDING PILOT STUDY Group 1 (5 subjects): MDMA 50 mg (3 subjects) placebo (1 subject) Group 2 (7 subjects): MDMA 75 mg (5 subjects) placebo (2 subjects) Group 3 (7 subjects): 100 mg de MDMA (5 subjects) placebo (2 subjects) Group 4 (7 subjects): 125 mg de MDMA (5 subjects) placebo (2 subjects) Group 5 (5 subjects): 150 mg de MDMA (3 subjects) placebo (1 subject) TOTAL SUBJECTS: 29 (MDMA: 21; placebo: 8) EFFICACY PILOT STUDY - Group 1 (15 subjects): MDMA (the most efficacy dose obtained from the dose-finding pilot study) - Group 2 (15 subjects): placebo PROPOSED STUDY DESIGNS

  3. Psychometric measures • A Strutured Clinical Interview based on the DSM-IV (the SCID). • The Scale of Severity of Symptoms of PTSD. • A Semi-Structured Interview regarding sexual aggression. • STAI/S. The STAI in its State version. • BDI. The Beck Depression Inventory. • HRS. The Hamilton Rating Scale for depression. • MFS-III. The Modified Fear Scale (assess specific fears related with a sexual assault). • A Maladjustment Scale. • SE/R. The Rosenger Self-Esteem Scale. • HRS-S. The Hallucinogen Rating Scale, HRS. • The UKU side-effects rating scale. • HAq. The Helping Alliance questionnaire.

  4. OBJECTIVES • To assess the security of different doses of MDMA in chronic PTSD population • To obtain preliminary data about the efficacy of MDMA in the treatment of PTSD • To familarize the therapeutic team with the treatment with MDMA and to refine the therapeutic approach • To assess how the proposed rating scales work in order to refine them in future studies

  5. TREATMENT PLAN

More Related